1-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)phenyl]-3-phenylurea | 1454657-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)phenyl]-3-phenylurea
• 英文别名: 1-[4-(3,4-dihydro-1H-2,7-naphthyridin-2-yl)phenyl]-3-phenylurea
• CAS: 1454657-19-2
• 化学式: C₂₁H₂₀N₄O
• 分子量: 344.416
• InChiKey: DETQEUBCKFGKNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  57.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)aniline dihydrochloride 、 异氰酸苯酯 以to give the title compound as an off-white solid (52 mg, 60%)的产率得到1-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)phenyl]-3-phenylurea
  参考文献：
  名称：

  KINASE INHIBITORS

  摘要：

  本发明涉及式I和式II化合物，其中变量如本文所定义。这些化合物能够调节酪氨酸激酶信号转导，以调节、调制和/或抑制异常细胞增殖。

  公开号：

  US20130237538A1

文献信息

• METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS
  申请人：ALLERGAN, INC.

  公开号：US20130237537A1

  公开（公告）日：2013-09-12

  The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及一种治疗眼科疾病和病况的方法，例如糖尿病视网膜病变、老年性黄斑变性、早产儿视网膜病变等，在一个受试者中，包括向该受试者施用至少一种式I的化合物的治疗有效量，或者该化合物的前药、药学上可接受的盐、拉丁混合物或对映体。式I的化合物能够调节酪氨酸激酶信号传导，以调节、调制和/或抑制异常细胞增殖。
• Kinase inhibitors
  申请人：Allergan, Inc.

  公开号：US08889870B2

  公开（公告）日：2014-11-18

  The present invention relates to compounds of formulae I and II wherein the variables are as defined herein. These compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及公式I和II的化合物，其中变量如本文所定义。这些化合物能够调节酪氨酸激酶信号传导，以调节、调节和/或抑制异常细胞增殖。
• Method of treating conditiions with kinase inhibitors
  申请人：Allergan, Inc.

  公开号：US09388176B2

  公开（公告）日：2016-07-12

  The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及一种治疗眼科疾病和病况（例如糖尿病视网膜病变、老年性黄斑变性、早产儿视网膜病变等）的方法，包括向受试者施用公式I中至少一种化合物的治疗有效量或其前药、药学上可接受的盐、外消旋混合物或对映体。公式I中的化合物能够调节酪氨酸激酶信号转导以调节、调制和/或抑制异常细胞增殖。
• METHOD OF TREATING OPHTHALMIC CONDITIONS WITH KINASE INHIBITORS
  申请人：ALLERGAN, INC.

  公开号：EP2825166A1

  公开（公告）日：2015-01-21
• DIHYDROPYRIDOPYRIMIDINE AND DIHYDRONAPHTHYRIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS OF ESPECIALLY VEGF AND PDGF
  申请人：ALLERGAN, INC.

  公开号：EP2825537A1

  公开（公告）日：2015-01-21